Friday, January 28, 2011

10,000 Strong Against Thyroid Cancer



FOR IMMEDIATE RELEASE

January 27, 2011
Orlando Florida
Stevie JoEllie's Cancer Care Fund differs greatly from other cancer care groups in that our focus is on patient assistance and access to care not research funding. The reason is simple, thyroid cancer is the fastest increasing newly diagnosed cancer in America today regardless of age, sex, race or ethnic background.

At a time of unprecedented unemployment rates, increasing "benefit" cuts by the private and public sector newly diagnosed thyroid cancer patients and survivors facing lifelong healthcare needs and seeking some form of access to medical care assistance has increased by 52% in the past year. While there are over 1,000 organizations nationwide dedicated exclusively to thyroid cancer research funding SJCCF is the sole organization focused exclusively on helping to relieve the financial burden on the patient and family living "with" thyroid cancer.

But we cant do it alone and we need your help and support today more than ever. We are enclosing a link to our 2011 Cause 10,000 Strong Against Thyroid Cancer. Our goal is to raise $100,000 via Causes.com by 12/31/2011 to continue developing and help sustain our access to care grant program for thyroid cancer patients and survivors.

Every one can help by donating a single dollar or sharing this donation link with your friends, family and network http://www.causes.com/sjccfthynet
                            
Disclosure: Stevie JoEllie's Cancer Care Fund is a Project Of United Charitable Programs Inc.a 501(c)3 Public Charity Tax ID #20-4286082 Program #102442.  Donations are tax deductible as allowed by law. All funds raised by Stevie JoEllie's Cancer Care Fund are received by UCP, which, for internal operating purposes, allocates the funds to the Project (SJCCFThyNet). The Program Manager, then makes recommendations for disbursements which are reviewed by UCP for approval


                    TOGETHER WE CAN SAVE LIVES.


################

No comments:

Post a Comment